Auritec Pharmaceuticals LLC is developing extended release drug delivery systems, with applications in treating a variety of life-threatening diseases. The company's proprietary Plexis technology combines a membrane-based, diffusion-driven release mechanism with drug particle sizing large enough to allow high drug loading but small enough to be injected. Auritec's Versa platform involves a core of a solid drug coated with a semi-permeable polymer-targeted and sustained drug delivery system. The Plexis platform may be used in the treatment of schizophrenia, Alzheimers, graft rejection, arthritis, macular edema and HIV. Auritecs Versa platform utilizes the technology behind the FDA approved Vitrasert and Retisert for sustained release implants of a wide range of solubilities over the timescale of months to years.